Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

GUT MICROBIOME PROFILES AND RISK OF COLORECTAL CANCER

K Liying
New York University School Of Medicinecity: New York    country: United States (us)

Grant 1R03CA159414-01A1 from National Cancer Institute

Abstract: Our hypothesis is that gut microbiome profiles are associated with risk of colorectal cancer. Altered gut microbiome may promote colorectal carcinogenesis by inducing chronic inflammation. Also, gut microbiota may be related to CRC risk by metabolizing food components, such as carcinogenic heterocyclic amines. However, past studies of microbial flora and colorectal cancer are limited to animal models and small human studies, both considering only a selected number of culturable microbial species. To our knowledge, no epidemiologic study has comprehensively evaluated the relationship of the human gut microbiome to risk of colorectal cancer using gene sequence-based approach. We propose an innovative study to comprehensively examine the relationship between gut microbiome profile and colorectal cancer risk in a case-control study (69 cases and 114 controls), with previously collected and lyophilized fecal biospecimens obtained before initiation of any treatment, in study samples collected by NCI with associated demographic and clinical information (Schiffman MH et al, Cancer Research, 1989). We will comprehensively survey common gut microbial species (including non-culturables) from fecal biospecimens by sequencing of the 16S rRNA microbial genes. We will 1) define the normal gut microbiome in the control group, and 2) examine if the gut microbiome differs between colorectal cancer cases and controls. As a secondary aim, we will evaluate intra-individual variability (temporal stability of gut microbiome profile collected at study recruitment and after 6 months in a subset of 20 randomly selected individuals from the control group. This project is timely and highly relevant to the goals of the NIH Roadmap and the NIH Human Microbiome Project (HMP). Results from this first comprehensive evaluation of the gut microbiome will identify colorectal cancer-related gut bacterial profiles and improve our understanding of the etiology of this disease. Understanding the temporal stability of the microbiome profile in this R03 grant will lay the foundation for subsequent R01 applications, proposing large-scale prospective evaluation with fecal biospecimen collection. Considering the significant public health burden of colorectal cancer as the second leading cause of cancer death in the US, and the potential importance of the microbiome in its causation, there is great need for the proposed R03 study. More than 160,000 cases of colorectalcancer are diagnosed annually in the US, and 57,000 patients die of the disease, making it the second leading cause of death from cancer among adults. We will determine the impact of microbes in the gut on risk for these diseases. Our study will identifying gut bacterial profiles related to colorectal cancer risk, providing direct leads to implement microbial prophylactic interventions

Keywords: Adult; Animal Model; anticancer research; base; Base Sequence; Behavior; Cancer Etiology; cancer risk; carcinogenesis; case control; Case-Control Studies; Cause of Death; Cessation of life; Chronic; Clinical; Collection; Colorectal; Colorectal Cancer; Control Groups; cost; cost effective; Culture Media; Development; Diagnosis; Dideoxy Chain Termination DNA Sequencing; Disease; disorder risk; Epidemiologic Studies; Esophageal; Etiology; Evaluation; Food; Foundations; Frequencies (time pattern); Genes; Goals; Grant; Growth; gut microbiota; Heterocyclic Amines; Histologic; Human; Human Microbiome; improved; Individual; Inflammation; Inflammatory; innovation; Intervention; Intestines; Malignant Neoplasms; Methods; Microbe; microbial; microbiome; novel; Patients; Premalignant; Primitive foregut structure; prophylactic; prospective; public health medicine (field); Relative (related person); Reporting; Risk; Risk Factors; RNA Sequences; RNA, Ribosomal, 16S; Sampling; Sampling Studies; Surveys; United States National Institutes of Health; Validation

Relevance: More than 160,000 cases of colorectalcancer are diagnosed annually in the US, and 57,000 patients die of the disease, making it the second leading cause of death from cancer among adults. We will determine the impact of microbes in the gut on risk for these diseases. Our study will identifying gut bacterial profiles related to colorectal cancer risk, providing direct leads to implement microbial prophylactic interventions

Project start date: 2012-03-01

Project end date: 2014-02-28

Budget start date: 1-MAR-2012

Budget end date: 28-FEB-2013

1R03CA159414-01A1 (2012): $84500


Sponsored Links Excellgen http://Excellgen.com

Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950
Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950